Certivia Laboratories, LLC.

According to the American Diabetes Association, liver disease affects up to 70% of those with Type 2 diabetes. If you live with Type 2 diabetes, you may be at risk for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition that can lead to cirrhosis, liver cancer and heart disease. The good news is that knowing your risk can help you take control of the disease. To better understand your MASH risk and learn how you can manage it, talk to your provider about Labcorp’s testing solutions for fatty liver disease. Our comprehensive portfolio can help with diagnosis and management of MASH so you and your care team can make informed decisions for your health. Explore our profiles and related tests: https://spr.ly/6044sDvu4 #DiabetesAwarenessMonth #MASH

An important advancement for patients with advanced gastric or gastroesophageal junction cancers: Labcorp is now offering the first FDA-approved companion diagnostic test for identifying those who may benefit from targeted treatment with VYLOY?. Timely access to this test, made possible by our participation in Roche's Day-One readiness program, means eligible patients can potentially start appropriate therapies sooner, which could make a significant difference in their care journeys. Learn more: https://spr.ly/6043sHGCW #GastricCancer #CancerDiagnostics #PersonalizedMedicine

Trust in Every Test. Certivialab ensures every test is performed with the highest standards of care and accuracy. Join us in providing unparalleled patient outcomes. We are growing, and doing so with quality. Email [email protected] to partner with us. #Toxicology #GeorgiaMedical #PatientCare

Revolutionize Your Diagnostics! Speed up your healthcare processes with Certivialab's CAP & CLIA-certified diagnostics. Our cutting-edge technology ensures accuracy and efficiency. Let's elevate your patient care together. Contact us at [email protected] for a game-changing partnership. #AtlantaHealthcare #LaboratoryServices #MedicalProfessionals